Can-Fite 在欧洲生物会议上发布了 Namodenoson 治疗胰腺癌和肝癌的数据。 Can-Fite releases Namodenoson treatment data for pancreatic and liver cancer at Bio Europe Conference.

Can-Fite BioPharma Ltd. 在生物欧洲会议上发布了 Namodenoson 治疗胰腺癌和肝癌的数据。 Can-Fite BioPharma Ltd. releases data on Namodenoson treatment for pancreatic and liver cancer at Bio Europe Conference. 他们的产品线包括治疗晚期肝癌和胰腺癌的 Namodenoson，该药物已被授权给多家公司，例如东欧的 Ewopharma、中国的 CMS 和韩国的 CKD。 Their pipeline includes Namodenoson for advanced liver and pancreatic cancer, which has been licensed to various companies such as Ewopharma for Eastern Europe, CMS in China, and CKD in South Korea. Can-Fite 专注于临床开发以及与专门从事药品分销的公司合作。 Can-Fite focuses on clinical development and partnering with companies specializing in pharmaceutical distribution.

文章

Street Insider

Market Screener

WallStreet Online

-- 显示更少 --

延伸阅读

相关故事